{"id":2649,"date":"2005-03-25T14:13:30","date_gmt":"2005-03-25T21:13:30","guid":{"rendered":"http:\/\/oralcancernews.org\/wp\/?p=2649"},"modified":"2009-03-27T14:14:03","modified_gmt":"2009-03-27T21:14:03","slug":"quality-of-life-mucositis-and-xerostomia-from-radiotherapy-for-head-and-neck-cancers-a-report-from-the-ncic-ctg-hn2-randomized-trial-of-an-antimicrobial-lozenge-to-prevent-mucositis","status":"publish","type":"post","link":"https:\/\/oralcancernews.org\/wp\/quality-of-life-mucositis-and-xerostomia-from-radiotherapy-for-head-and-neck-cancers-a-report-from-the-ncic-ctg-hn2-randomized-trial-of-an-antimicrobial-lozenge-to-prevent-mucositis\/","title":{"rendered":"Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: A report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis"},"content":{"rendered":"<ul class=\"bullets\">\n<li><strong>3\/25\/2005<\/strong><\/li>\n<li><strong>Vancourver, British Columbia, Canada<\/strong><\/li>\n<li><strong>Graeme G Duncan et al.<\/strong><\/li>\n<li><strong>Head Neck, March 21, 2005<\/strong><\/li>\n<\/ul>\n<p>Background:<br \/>\nThe National Cancer Institute of Canada Clinical Trials Group undertook a multicenter, randomized, double-blind controlled trial of an oral antimicrobial versus placebo to prevent and treat mucositis. We present the quality of life (QOL) analysis for this trial.<\/p>\n<p>Methods:<br \/>\nOne hundred thirty-eight patients were randomly assigned. QOL data were collected every 2 weeks before, during, and after radiotherapy. The European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C30) and a Trial Specific Checklist (TSC) were used.<\/p>\n<p>Results:<br \/>\nThe antimicrobial lozenge did not impact QOL. The principal acute side effect of radiotherapy is oral pain, affecting more than 90% of patients. Role function is impacted during treatment, and patients experience fatigue. Appetite was reported to markedly increase during radiotherapy. There was a dramatic and persistent increase in dry mouth.<\/p>\n<p>Conclusions:<br \/>\nThis study highlights the benefits of combining the EORTC QLQ-30 with an &#8220;oral&#8221; TSC in a randomized controlled trial and provides valuable baseline data for their use with an objective mucositis scoring system.<\/p>\n<p>Authors:<br \/>\nGraeme G Duncan, Joel B Epstein, Dongsheng Tu, Samy El Sayed, Andrea Bezjak, Jon Ottaway, and Joe Pater<\/p>\n<p>Authors&#8217; Affiliation:<br \/>\nDepartment of Radiation Oncology, British Columbia Cancer Agency, Vancouver Centre, 600 West 10th Ave, Vancouver, BC, Canada<\/p>\n","protected":false},"excerpt":{"rendered":"<p>3\/25\/2005 Vancourver, British Columbia, Canada Graeme G Duncan et al. Head Neck, March 21, 2005 Background: The National Cancer Institute of Canada Clinical Trials Group undertook a multicenter, randomized, double-blind controlled trial of an oral antimicrobial versus placebo to prevent and treat mucositis. We present the quality of life (QOL) analysis for this trial. Methods: One hundred thirty-eight patients were randomly assigned. QOL data were collected every 2 weeks before, during, and after radiotherapy. The European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C30) and a Trial Specific Checklist (TSC) were used. Results: The antimicrobial lozenge did not impact QOL. The principal acute side effect of radiotherapy is oral pain, affecting more than 90% of patients. Role function is impacted during treatment, and patients experience fatigue. Appetite was reported to markedly increase during radiotherapy. There was a dramatic and persistent increase in dry mouth. Conclusions: This study highlights the benefits of combining the EORTC QLQ-30 with an &#8220;oral&#8221; TSC in a randomized controlled trial and provides valuable baseline data for their use with an objective mucositis scoring system. Authors: Graeme G Duncan, Joel B Epstein, Dongsheng Tu, Samy El Sayed, Andrea Bezjak, Jon Ottaway, and Joe Pater Authors&#8217; Affiliation: Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver Centre, 600 West 10th Ave, Vancouver, BC, Canada<\/p>\n","protected":false},"author":41,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[787],"tags":[],"class_list":["post-2649","post","type-post","status-publish","format-standard","hentry","category-oral-cancer-news-archive"],"_links":{"self":[{"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/posts\/2649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/users\/41"}],"replies":[{"embeddable":true,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/comments?post=2649"}],"version-history":[{"count":1,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/posts\/2649\/revisions"}],"predecessor-version":[{"id":2650,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/posts\/2649\/revisions\/2650"}],"wp:attachment":[{"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/media?parent=2649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/categories?post=2649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/tags?post=2649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}